WEZENLA 45 mg/0.5 ml sol inj 45 mg 1 pce

7680701880014 CH-70188 L04AC05 07.15.0.

Active substances:

Ustekinumabum

No images available

Details

Product number
7018801
CPT
-
Packaging group
1
Unit
Fertigspritze(n)
Composition
ustekinumabum 45 mg, saccharum, histidinum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 0.5 ml.

Articles (1)

Wezenla 45 mg/0.5 ml, Injektionslösung in einer Fertigspritze
Injektionslösung
1
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
29/04/2026
Patient information leaflet
Français
29/04/2026
Patient information leaflet
Italien
29/04/2026

Detailed composition

Substance Quantity Type Category
ustekinumabum
45.0 MG Substance Wirkstoff (Principe actif)
saccharum
- Substance HNIDK
histidinum
- Substance HNIDK
polysorbatum 80
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK

Reimbursement information

Public price
CHF 1540.15
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/05/2026

Authorization holder

Amgen Switzerland AG

6343 Risch

Authorization information

Swissmedic authorization number
70188
Drug name
Wezenla, Injektionslösung in einer Fertigspritze
Galenic form
INLFS
ATC Code
L04AC05
Authorization status
Z
Dispensation category
B
First authorization
23/07/2025
Authorization expiration date
22/07/2030
IT number
07.15.0.
Domain
Human medicine
Field of application
Plaque-Psoriasis ab 6 Jahren, Psoriasis-Arthritis, Morbus Crohn, Ulcerative Colitis

Packaging details

Description (FR)
WEZENLA 45 mg/0.5 ml sol inj 45 mg 1 pce
Description (DE)
WEZENLA 45 mg/0.5 ml Inj Lös 45 mg 1 Stk
Market launch
29/04/2026
Narcotic (BTM)
No

Other packaging sizes

WEZENLA 90 mg/1 ml sol inj 90 mg 1 pce
1 FESP
GTIN: 7680701880021
View
Buy us a coffee Explore the data